News & Resources

2016 Press Releases

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Media Contact:
Erika Hackmann
Y&R PR
Phone: 212-303-2305
Email:Erika.Hackmann@yr.com

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/19/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl prolonged release) for Ten Countries in the Middle EastPrinter Friendly Version
12/19/16Orexigen Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017Printer Friendly Version
12/08/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and IrelandPrinter Friendly Version
11/16/16Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug AddictionPrinter Friendly Version
11/08/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave® (naltrexone HCl / bupropion HCl extended release) in Australia and New ZealandPrinter Friendly Version
11/03/16Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016Printer Friendly Version
11/02/16Orexigen Therapeutics to Present at 25th Annual Credit Suisse Healthcare ConferencePrinter Friendly Version
10/21/16Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2016 Financial Results on November 3, 2016Printer Friendly Version
09/07/16Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment ConferencePrinter Friendly Version
08/30/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)Printer Friendly Version
08/04/16Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016Printer Friendly Version
08/01/16Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales OrganizationPrinter Friendly Version
08/01/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmacéuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in SpainPrinter Friendly Version
07/21/16Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016Printer Friendly Version
07/08/16Orexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 Annual Meeting and Reverse Stock SplitPrinter Friendly Version
06/22/16Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
06/08/16Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent LitigationPrinter Friendly Version
06/08/16Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFOPrinter Friendly Version
05/27/16Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from BoardPrinter Friendly Version
05/27/16Orexigen Announces Upcoming Presentations at European Obesity Summit 2016Printer Friendly Version
05/26/16Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
05/23/16Orexigen Appoints New Member of Board of Directors and Announces Senior Management ChangesPrinter Friendly Version
05/04/16Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016Printer Friendly Version
05/03/16Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and DevelopmentPrinter Friendly Version
05/03/16Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care ConferencePrinter Friendly Version
05/02/16Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult PatientsPrinter Friendly Version
04/28/16Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the World Obesity FederationPrinter Friendly Version
04/25/16Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New EmployeesPrinter Friendly Version
04/20/16Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on May 4, 2016Printer Friendly Version
03/15/16Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and Eastern Europe Distribution Agreement with ValeantPrinter Friendly Version
03/15/16Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicinePrinter Friendly Version
03/15/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern European Countries and TurkeyPrinter Friendly Version
03/15/16Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United StatesPrinter Friendly Version
02/26/16Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015Printer Friendly Version
02/19/16Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Full Year 2015 Financial Results on February 26, 2016Printer Friendly Version
02/18/16Orexigen Therapeutics to Speak at the RBC Capital Markets 2016 Healthcare ConferencePrinter Friendly Version
02/02/16Orexigen Therapeutics to Speak at Upcoming Investor ConferencesPrinter Friendly Version
01/11/16Orexigen announces 2016 financial outlook and key prioritiesPrinter Friendly Version
01/08/16Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP, Global Human ResourcesPrinter Friendly Version
01/05/16Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare ConferencePrinter Friendly Version